Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-668 IR · 1 trial · 1 indication
Cmax of ABBV-668
Tmax of ABBV-668
Terminal phase elimination rate constant (beta) of ABBV-668
Terminal phase elimination half-life of ABBV-668
AUCt of ABBV-668
AUCinf of ABBV-688
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study
| Arm | Type | Description |
|---|---|---|
| ABBV-668 Regimen A | EXPERIMENTAL | Participants will receive ABBV-668 Immediate Release (IR) capsules on Day 1 under fasting conditions |
| ABBV-668 Regimen B | EXPERIMENTAL | Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 1 administered on day 1 under fasting conditions |
| ABBV-668 Regimen C | EXPERIMENTAL | Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 1 administered on day 1 under fed conditions |
| ABBV-668 Regimen D | EXPERIMENTAL | Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 2 administered on day 1 under fasting conditions |
| ABBV-668 Regimen E | EXPERIMENTAL | Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 2 administered on day 1 under fed conditions |
| ABBV-668 Regimen F | EXPERIMENTAL | Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 3 administered on day 1 under fasting conditions |
| ABBV-668 Regimen G | EXPERIMENTAL | Participants will receive ABBV-668 Extended Release (ER) tablets Formulation 3 administered on day 1 under fed conditions |
| Name | Type | Description |
|---|---|---|
| ABBV-668 IR | DRUG | • Oral Capsule |
| ABBV-668 ER | DRUG | • Oral Tablets |
Inclusion Criteria: * BMI is ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at screening. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG. Exclusion Criteria: * History of any...
ABBV-668 IR is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial assessing its relative bioavailability and food effect. The drug is not approved and remains under investigation for its intended use.
ABBV-668 IR is developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical trials to evaluate the drug's properties in adult participants.
ABBV-668 IR is in Phase 1 clinical development. One Phase 1 trial has been completed, involving 25 healthy adult volunteers in the United States. The drug is investigational and has not been approved by regulatory authorities.
ABBV-668 IR has one completed clinical trial, NCT06477926, titled 'A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants.' This Phase 1 study enrolled 25 healthy volunteers in the United States.
ABBV-668 IR is a formulation of the drug ABBV-668, with 'IR' indicating an immediate-release version. The completed trial also evaluated extended-release formulations of ABBV-668, comparing their bioavailability and food effects in healthy adults.